Segments of Business and Geographic Areas - Sales by Segment of Business (Details) $ in Millions	12 Months Ended
	Dec. 28, 2025 USD ($) segment	Dec. 29, 2024 USD ($)	Dec. 31, 2023 USD ($)
Segment Reporting Information [Line Items]
Number of segments \| segment	2
Sales to Customers	$ 94,193	$ 88,821	$ 85,159
% Change	6.00%	4.30%
Innovative Medicine
Segment Reporting Information [Line Items]
Sales to Customers	$ 60,401	$ 56,964	54,759
% Change	6.00%	4.00%
Innovative Medicine \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 15,728	$ 17,828	18,052
% Change	(11.80%)	(1.20%)
Innovative Medicine \| Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers	$ 3,241	$ 3,396	4,418
% Change	(4.60%)	(23.10%)
Innovative Medicine \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 7,837	$ 7,115	7,140
% Change	10.10%	(0.40%)
Innovative Medicine \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 25,380	$ 20,781	17,661
% Change	22.10%	17.70%
Innovative Medicine \| Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers	$ 4,437	$ 4,282	3,815
% Change	3.60%	12.30%
Innovative Medicine \| Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers	$ 3,778	$ 3,562	3,671
% Change	6.10%	(3.00%)
MedTech
Segment Reporting Information [Line Items]
Sales to Customers	$ 33,792	$ 31,857	30,400
% Change	6.10%	4.80%
MedTech \| Cardiovascular
Segment Reporting Information [Line Items]
Sales to Customers	$ 8,928	$ 7,707	6,350
% Change	15.80%	21.40%
MedTech \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 9,258	$ 9,158	8,942
% Change	1.10%	2.40%
MedTech \| Surgery
Segment Reporting Information [Line Items]
Sales to Customers	$ 10,137	$ 9,845	10,037
% Change	3.00%	(1.90%)
MedTech \| Vision
Segment Reporting Information [Line Items]
Sales to Customers	$ 5,468	$ 5,146	5,072
% Change	6.30%	1.50%
CARVYKTI \| Innovative Medicine \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,887	$ 963	500
% Change	95.90%	92.70%
DARZALEX \| Innovative Medicine \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 14,351	$ 11,670	9,744
% Change	23.00%	19.80%
ERLEADA \| Innovative Medicine \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 3,574	$ 2,999	2,387
% Change	19.20%	25.60%
IMBRUVICA \| Innovative Medicine \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,823	$ 3,038	3,264
% Change	(7.10%)	(6.90%)
RYBREVANT/LAZCLUZE \| Innovative Medicine \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 734	$ 327	93
TALVEY \| Innovative Medicine \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 463	287	63
% Change	61.30%
TECVAYLI \| Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 670	$ 549	395
% Change	22.10%	38.80%
ZYTIGA/abiraterone acetate \| Innovative Medicine \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 502	$ 631	887
% Change	(20.40%)	(28.80%)
Other Oncology \| Innovative Medicine \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 376	$ 317	328
% Change	18.50%	(3.40%)
Remicade \| Innovative Medicine \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,768	$ 1,605	1,839
% Change	10.20%	(12.80%)
Simponi/Simponi Aria \| Innovative Medicine \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,668	$ 2,190	2,197
% Change	21.80%	(0.30%)
Stelara \| Innovative Medicine \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 6,078	$ 10,361	10,858
% Change	(41.30%)	(4.60%)
Tremfya \| Innovative Medicine \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 5,155	$ 3,670	3,147
% Change	40.50%	16.60%
Other Immunology \| Innovative Medicine \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 61	$ 3	11
% Change		(74.10%)
CAPLYTA \| Innovative Medicine \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	700	$ 0	0
% Change		0.00%
CONCERTA/Methylphenidate \| Innovative Medicine \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 584	$ 641	783
% Change	(9.00%)	(18.10%)
INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA \| Innovative Medicine \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 3,810	$ 4,222	4,115
% Change	(9.80%)	2.60%
SPRAVATO \| Innovative Medicine \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,696	$ 1,077	689
% Change	57.40%	56.40%
OTHER NEUROSCIENCE \| Innovative Medicine \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,048	$ 1,175	1,553
% Change	(10.90%)	(24.30%)
OPSUMIT \| Innovative Medicine \| Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,325	$ 2,225	1,973
% Change	4.50%	12.80%
UPTRAVI \| Innovative Medicine \| Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,902	$ 1,817	1,582
% Change	4.70%	14.90%
Other Pulmonary Hypertension \| Innovative Medicine \| Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers	$ 209	$ 240	260
% Change	(12.70%)	(7.70%)
EDURANT/rilpivirine \| Innovative Medicine \| Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,486	$ 1,272	1,150
% Change	16.90%	10.60%
PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA \| Innovative Medicine \| Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,579	$ 1,712	1,854
% Change	(7.70%)	(7.70%)
Other Infectious Diseases \| Innovative Medicine \| Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers	$ 175	$ 412	1,414
% Change	(57.50%)
XARELTO \| Innovative Medicine \| Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,633	$ 2,373	2,365
% Change	11.00%	0.30%
Other \| Innovative Medicine \| Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,145	$ 1,189	1,306
% Change	(3.70%)	(8.90%)
ELECTROPHYSIOLOGY \| MedTech \| Cardiovascular
Segment Reporting Information [Line Items]
Sales to Customers	$ 5,634	$ 5,267	4,688
% Change	7.00%	12.30%
Abiomed \| MedTech \| Cardiovascular
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,751	$ 1,496	1,306
% Change	17.10%	14.50%
Shockwave Medical, Inc. \| MedTech \| Cardiovascular
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,146	$ 564	0
other cardiovascular \| MedTech \| Cardiovascular
Segment Reporting Information [Line Items]
Sales to Customers	$ 397	$ 380	356
% Change	4.30%	6.90%
HIPS \| MedTech \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,674	$ 1,638	1,560
% Change	2.10%	5.00%
KNEES \| MedTech \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,587	$ 1,545	1,456
% Change	2.70%	6.10%
TRAUMA \| MedTech \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 3,146	$ 3,049	2,979
% Change	3.20%	2.30%
SPINE,SPORTS & OTHER \| MedTech \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,852	$ 2,926	2,947
% Change	(2.50%)	(0.70%)
ADVANCED \| MedTech \| Surgery
Segment Reporting Information [Line Items]
Sales to Customers	$ 4,577	$ 4,488	4,671
% Change	2.00%	(3.90%)
GENERAL \| MedTech \| Surgery
Segment Reporting Information [Line Items]
Sales to Customers	$ 5,560	$ 5,358	5,366
% Change	3.80%	(0.20%)
CONTACT LENSES/OTHER \| MedTech \| Vision
Segment Reporting Information [Line Items]
Sales to Customers	$ 3,910	$ 3,733	3,702
% Change	4.80%	0.80%
SURGICAL \| MedTech \| Vision
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,558	$ 1,413	1,370
% Change	10.20%	3.20%
United States
Segment Reporting Information [Line Items]
Sales to Customers	$ 53,752	$ 50,302	46,444
% Change	6.90%	8.30%
United States \| Innovative Medicine
Segment Reporting Information [Line Items]
Sales to Customers	$ 36,344	$ 33,970	31,169
% Change	7.00%	9.00%
United States \| Innovative Medicine \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 9,872	$ 11,355	11,539
% Change	(13.10%)	(1.60%)
United States \| Innovative Medicine \| Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,264	$ 1,354	1,500
% Change	(6.60%)	(9.80%)
United States \| Innovative Medicine \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 5,151	$ 4,398	4,065
% Change	17.10%	8.20%
United States \| Innovative Medicine \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 13,659	$ 10,854	8,462
% Change	25.80%	28.30%
United States \| Innovative Medicine \| Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers	$ 3,223	$ 3,143	2,697
% Change	2.60%	16.50%
United States \| Innovative Medicine \| Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers	$ 3,175	$ 2,866	2,906
% Change	10.80%	(1.40%)
United States \| MedTech
Segment Reporting Information [Line Items]
Sales to Customers	$ 17,408	$ 16,332	15,275
% Change	6.60%	6.90%
United States \| MedTech \| Cardiovascular
Segment Reporting Information [Line Items]
Sales to Customers	$ 5,305	$ 4,513	3,633
% Change	17.50%	24.20%
United States \| MedTech \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 5,720	$ 5,689	5,525
% Change	0.50%	3.00%
United States \| MedTech \| Surgery
Segment Reporting Information [Line Items]
Sales to Customers	$ 4,157	$ 4,003	4,031
% Change	3.90%	(0.70%)
United States \| MedTech \| Vision
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,225	$ 2,128	2,086
% Change	4.60%	2.00%
United States \| CARVYKTI \| Innovative Medicine \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,492	$ 869	469
% Change	71.60%	85.20%
United States \| DARZALEX \| Innovative Medicine \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 8,266	$ 6,588	5,277
% Change	25.50%	24.80%
United States \| ERLEADA \| Innovative Medicine \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,453	$ 1,282	1,065
% Change	13.40%	20.30%
United States \| IMBRUVICA \| Innovative Medicine \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 892	$ 1,020	1,051
% Change	(12.50%)	(3.00%)
United States \| RYBREVANT/LAZCLUZE \| Innovative Medicine \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 534	$ 257	66
United States \| TALVEY \| Innovative Medicine \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 340	241	56
% Change	40.90%
United States \| TECVAYLI \| Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 444	$ 418	334
% Change	6.30%	25.30%
United States \| ZYTIGA/abiraterone acetate \| Innovative Medicine \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 23	$ 34	50
% Change	(33.20%)	(32.20%)
United States \| Other Oncology \| Innovative Medicine \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 214	$ 145	93
% Change	47.50%	55.90%
United States \| Remicade \| Innovative Medicine \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,171	$ 1,009	1,143
% Change	16.00%	(11.70%)
United States \| Simponi/Simponi Aria \| Innovative Medicine \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,193	$ 1,082	1,124
% Change	10.30%	(3.80%)
United States \| Stelara \| Innovative Medicine \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 3,847	$ 6,720	6,966
% Change	(42.70%)	(3.50%)
United States \| Tremfya \| Innovative Medicine \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 3,529	$ 2,443	2,147
% Change	44.50%	13.70%
United States \| Other Immunology \| Innovative Medicine \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 59	$ 3	11
% Change		(74.10%)
United States \| CAPLYTA \| Innovative Medicine \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	700	$ 0	0
% Change		0.00%
United States \| CONCERTA/Methylphenidate \| Innovative Medicine \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 82	$ 134	230
% Change	(38.60%)	(41.70%)
United States \| INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA \| Innovative Medicine \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,725	$ 3,125	2,897
% Change	(12.80%)	7.90%
United States \| SPRAVATO \| Innovative Medicine \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,485	$ 929	589
% Change	59.90%	57.80%
United States \| OTHER NEUROSCIENCE \| Innovative Medicine \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 159	$ 210	349
% Change	(24.50%)	(39.80%)
United States \| OPSUMIT \| Innovative Medicine \| Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,633	$ 1,557	1,292
% Change	4.80%	20.50%
United States \| UPTRAVI \| Innovative Medicine \| Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,536	$ 1,511	1,326
% Change	1.70%	13.90%
United States \| Other Pulmonary Hypertension \| Innovative Medicine \| Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers	$ 54	$ 75	79
% Change	(27.00%)	(5.10%)
United States \| EDURANT/rilpivirine \| Innovative Medicine \| Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers	$ 26	$ 31	35
% Change	(18.40%)	(10.00%)
United States \| PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA \| Innovative Medicine \| Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,226	$ 1,311	1,446
% Change	(6.50%)	(9.40%)
United States \| Other Infectious Diseases \| Innovative Medicine \| Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers	$ 12	$ 11	19
% Change	6.60%	(41.00%)
United States \| XARELTO \| Innovative Medicine \| Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,633	$ 2,373	2,365
% Change	11.00%	0.30%
United States \| Other \| Innovative Medicine \| Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers	$ 542	$ 494	541
% Change	9.80%	(8.80%)
United States \| ELECTROPHYSIOLOGY \| MedTech \| Cardiovascular
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,891	$ 2,738	2,458
% Change	5.60%	11.40%
United States \| Abiomed \| MedTech \| Cardiovascular
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,393	$ 1,213	1,066
% Change	14.90%	13.70%
United States \| Shockwave Medical, Inc. \| MedTech \| Cardiovascular
Segment Reporting Information [Line Items]
Sales to Customers	$ 897	$ 442	0
United States \| other cardiovascular \| MedTech \| Cardiovascular
Segment Reporting Information [Line Items]
Sales to Customers	$ 124	$ 120	109
% Change	3.10%	10.70%
United States \| HIPS \| MedTech \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,080	$ 1,057	996
% Change	2.10%	6.20%
United States \| KNEES \| MedTech \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 924	$ 922	896
% Change	0.20%	2.90%
United States \| TRAUMA \| MedTech \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,058	$ 2,013	1,949
% Change	2.20%	3.30%
United States \| SPINE,SPORTS & OTHER \| MedTech \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,658	$ 1,696	1,684
% Change	(2.20%)	0.70%
United States \| ADVANCED \| MedTech \| Surgery
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,900	$ 1,838	1,833
% Change	3.40%	0.20%
United States \| GENERAL \| MedTech \| Surgery
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,258	$ 2,165	2,198
% Change	4.30%	(1.50%)
United States \| CONTACT LENSES/OTHER \| MedTech \| Vision
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,754	$ 1,684	1,626
% Change	4.10%	3.60%
United States \| SURGICAL \| MedTech \| Vision
Segment Reporting Information [Line Items]
Sales to Customers	$ 471	$ 444	460
% Change	6.10%	(3.40%)
Non-US
Segment Reporting Information [Line Items]
Sales to Customers	$ 40,441	$ 38,519	38,715
% Change	5.00%	(0.50%)
Non-US \| Innovative Medicine
Segment Reporting Information [Line Items]
Sales to Customers	$ 24,057	$ 22,994	23,590
% Change	4.60%	(2.50%)
Non-US \| Innovative Medicine \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 5,856	$ 6,473	6,513
% Change	(9.50%)	(0.60%)
Non-US \| Innovative Medicine \| Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,977	$ 2,042	2,918
% Change	(3.20%)	(30.00%)
Non-US \| Innovative Medicine \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,686	$ 2,718	3,076
% Change	(1.20%)	(11.60%)
Non-US \| Innovative Medicine \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 11,721	$ 9,926	9,199
% Change	18.10%	7.90%
Non-US \| Innovative Medicine \| Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,214	$ 1,140	1,117
% Change	6.50%	2.00%
Non-US \| Innovative Medicine \| Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers	$ 603	$ 696	765
% Change	(13.30%)	(9.10%)
Non-US \| MedTech
Segment Reporting Information [Line Items]
Sales to Customers	$ 16,384	$ 15,525	15,125
% Change	5.50%	2.60%
Non-US \| MedTech \| Cardiovascular
Segment Reporting Information [Line Items]
Sales to Customers	$ 3,623	$ 3,194	2,717
% Change	13.40%	17.60%
Non-US \| MedTech \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 3,538	$ 3,470	3,417
% Change	2.00%	1.50%
Non-US \| MedTech \| Surgery
Segment Reporting Information [Line Items]
Sales to Customers	$ 5,980	$ 5,842	6,006
% Change	2.40%	(2.70%)
Non-US \| MedTech \| Vision
Segment Reporting Information [Line Items]
Sales to Customers	$ 3,243	$ 3,018	2,986
% Change	7.40%	1.10%
Non-US \| CARVYKTI \| Innovative Medicine \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 395	$ 94	30
Non-US \| DARZALEX \| Innovative Medicine \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 6,085	$ 5,082	4,467
% Change	19.70%	13.80%
Non-US \| ERLEADA \| Innovative Medicine \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,121	$ 1,717	1,322
% Change	23.50%	29.80%
Non-US \| IMBRUVICA \| Innovative Medicine \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,931	$ 2,018	2,214
% Change	(4.30%)	(8.80%)
Non-US \| RYBREVANT/LAZCLUZE \| Innovative Medicine \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 200	$ 70	27
Non-US \| TALVEY \| Innovative Medicine \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	123	46	7
Non-US \| TECVAYLI \| Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 226	131	61
% Change	72.80%
Non-US \| ZYTIGA/abiraterone acetate \| Innovative Medicine \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 480	$ 597	837
% Change	(19.70%)	(28.60%)
Non-US \| Other Oncology \| Innovative Medicine \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 162	$ 172	235
% Change	(6.00%)	(26.80%)
Non-US \| Remicade \| Innovative Medicine \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 523	$ 497	549
% Change	5.30%	(9.50%)
Non-US \| Simponi/Simponi Aria \| Innovative Medicine \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,475	$ 1,108	1,073
% Change	33.10%	3.30%
Non-US \| Stelara \| Innovative Medicine \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,230	$ 3,641	3,892
% Change	(38.70%)	(6.40%)
Non-US \| Tremfya \| Innovative Medicine \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,626	$ 1,227	999
% Change	32.50%	22.80%
Non-US \| Other Immunology \| Innovative Medicine \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 2	$ 0	0
% Change		0.00%
Non-US \| CAPLYTA \| Innovative Medicine \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 0	$ 0	0
% Change	0.00%	0.00%
Non-US \| CONCERTA/Methylphenidate \| Innovative Medicine \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 502	$ 507	554
% Change	(1.20%)	(8.40%)
Non-US \| INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA \| Innovative Medicine \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,085	$ 1,097	1,218
% Change	(1.10%)	(9.90%)
Non-US \| SPRAVATO \| Innovative Medicine \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 210	$ 148	100
% Change	41.90%	48.20%
Non-US \| OTHER NEUROSCIENCE \| Innovative Medicine \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 889	$ 965	1,204
% Change	(7.90%)	(19.80%)
Non-US \| OPSUMIT \| Innovative Medicine \| Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers	$ 692	$ 668	681
% Change	3.70%	(1.90%)
Non-US \| UPTRAVI \| Innovative Medicine \| Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers	$ 366	$ 307	255
% Change	19.40%	20.10%
Non-US \| Other Pulmonary Hypertension \| Innovative Medicine \| Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers	$ 155	$ 165	182
% Change	(6.20%)	(9.30%)
Non-US \| EDURANT/rilpivirine \| Innovative Medicine \| Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,461	$ 1,241	1,115
% Change	17.70%	11.20%
Non-US \| PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA \| Innovative Medicine \| Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers	$ 353	$ 401	408
% Change	(11.90%)	(1.70%)
Non-US \| Other Infectious Diseases \| Innovative Medicine \| Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers	$ 163	$ 401	1,395
% Change	(59.30%)
Non-US \| XARELTO \| Innovative Medicine \| Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers	$ 0	$ 0	0
% Change	0.00%	0.00%
Non-US \| Other \| Innovative Medicine \| Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers	$ 603	$ 696	765
% Change	(13.30%)	(9.10%)
Non-US \| ELECTROPHYSIOLOGY \| MedTech \| Cardiovascular
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,743	$ 2,529	2,230
% Change	8.50%	13.40%
Non-US \| Abiomed \| MedTech \| Cardiovascular
Segment Reporting Information [Line Items]
Sales to Customers	$ 358	$ 284	240
% Change	26.40%	18.20%
Non-US \| Shockwave Medical, Inc. \| MedTech \| Cardiovascular
Segment Reporting Information [Line Items]
Sales to Customers	$ 249	$ 122	0
Non-US \| other cardiovascular \| MedTech \| Cardiovascular
Segment Reporting Information [Line Items]
Sales to Customers	$ 273	$ 260	247
% Change	4.90%	5.30%
Non-US \| HIPS \| MedTech \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 594	$ 581	564
% Change	2.20%	3.00%
Non-US \| KNEES \| MedTech \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 663	$ 623	559
% Change	6.50%	11.30%
Non-US \| TRAUMA \| MedTech \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,088	$ 1,036	1,030
% Change	5.00%	0.60%
Non-US \| SPINE,SPORTS & OTHER \| MedTech \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,193	$ 1,230	1,263
% Change	(3.00%)	(2.60%)
Non-US \| ADVANCED \| MedTech \| Surgery
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,678	$ 2,650	2,837
% Change	1.00%	(6.60%)
Non-US \| GENERAL \| MedTech \| Surgery
Segment Reporting Information [Line Items]
Sales to Customers	$ 3,302	$ 3,192	3,168
% Change	3.40%	0.80%
Non-US \| CONTACT LENSES/OTHER \| MedTech \| Vision
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,157	$ 2,049	2,076
% Change	5.30%	(1.30%)
Non-US \| SURGICAL \| MedTech \| Vision
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,086	$ 969	910
% Change	12.10%	6.50%
UNITED STATES Exports \| Remicade \| Innovative Medicine \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 74	$ 98	$ 147
% Change	(24.80%)	(33.00%)

JOHNSON & JOHNSON 10-K